Intensity Therapeutics's operating income is $-11M.
Get informed when a big investor buys or sells
+ FollowAs of Mar 31, 2026
Trailing 12 months ending Mar 31, 2026
The latest operating income for INTS is $-11M as of March 2026. That compares with $-15M in the prior-year period — up 27.1% year over year. Investors often review this figure alongside Intensity Therapeutics's historical trend and sector peers before judging valuation or financial health.
Over the past year, INTS's operating income moved from $-15M to $-11M — a 27.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Intensity Therapeutics's operating scale or balance-sheet position.
A operating income figure of $-11M for INTS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.
After noting INTS's operating income ($-11M), review year-over-year change from $-15M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.